Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.
Fortrea Holdings Inc. (NASDAQ: FTRE) is a global contract research organization and provider of clinical development solutions to the life sciences industry. This news page aggregates company press releases and market updates related to FTRE, giving readers a focused view of how Fortrea operates as a public company and clinical development partner.
According to its own descriptions, Fortrea partners with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies. News about the company frequently highlights its work in phase I–IV clinical trial management, clinical pharmacology and consulting services, as well as its experience across more than 20 therapeutic areas and operations in about 100 countries.
Visitors can expect news items covering a range of topics, including quarterly and year-to-date financial results, guidance updates, cost-saving initiatives, and capital structure actions such as tender offers for senior secured notes. Fortrea also issues releases on leadership and governance developments, such as board appointments and executive hires, and on strategic collaborations with other organizations involved in areas like cell and gene therapy development and delivery.
Because Fortrea is listed on The NASDAQ Stock Market LLC under the symbol FTRE, its news flow also includes announcements about participation in healthcare and investor conferences, earnings calls and webcasts. Together, these updates provide insight into how Fortrea manages its clinical development services business, interacts with the investment community and responds to developments in its operating environment.
For investors, analysts and industry observers, following FTRE news offers a way to monitor the company’s financial reporting, governance changes, collaborations and other material events that Fortrea discloses through press releases and related communications.
Fortrea (Nasdaq: FTRE) announced on November 17, 2025 the appointment of Agnieszka M. Gallagher as general counsel. Gallagher will lead the company’s legal strategy and operations, serve as corporate secretary and chief compliance officer, and join Fortrea’s leadership team.
Gallagher brings more than 25 years of experience across life sciences, biotech, diagnostics, pharmaceutical and medtech sectors, including roles as chief legal officer at Standard Biotools where she was involved in its merger with SomaLogic, and senior legal and compliance positions at Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic and Pfizer. She succeeds J. Stillman Hanson, who is leaving after a planned transition period.
Fortrea (Nasdaq: FTRE) reported third-quarter 2025 continuing-operations results with Q3 revenue of $701.3M and a Q3 adjusted EBITDA of $50.7M. GAAP net loss for the quarter was $15.9M and adjusted net income was $11.7M (diluted EPS $0.12). Backlog stood at $7,644M and book-to-bill was 1.13x. Year-to-date revenue was $2,062.9M, while YTD GAAP net loss was $953.7M, which included a $797.9M non-cash goodwill impairment impacting EPS by $8.81. The company raised full-year 2025 revenue guidance to $2,700M–$2,750M and narrowed adjusted EBITDA guidance to $175M–$195M.
Management said cost-saving initiatives remain on track and there were no impairment indicators in Q3.
Fortrea (Nasdaq: FTRE) commenced a cash tender offer to purchase up to $75,744,000 aggregate principal of its outstanding 7.500% Senior Secured Notes due 2030, effective October 20, 2025. The offer price is $1,000 per $1,000 principal plus accrued interest; the Tender Offer will expire at 5:00 p.m. New York time on November 18, 2025 unless extended.
The principal purpose is to comply with indenture covenants tied to net proceeds from Fortrea’s June 2024 divestiture; funding is expected from cash on hand and/or other liquidity sources. Acceptance is subject to conditions and possible proration. Holders may withdraw tenders prior to expiration.
Fortrea (Nasdaq: FTRE) will release its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. The company will host a conference call at 8:00 am ET that day to review results and hold a Q&A session.
Participants must register on the Fortrea Investor Relations website and are advised to join at least 10 minutes early to avoid delays. The call will be available via an earnings webcast, and a replay will be posted shortly after the event in the events and presentations section of the Fortrea Investor Relations website.
Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has announced the appointment of William Sharbaugh to its Board of Directors. Sharbaugh brings over three decades of pharmaceutical industry experience with expertise in finance, operations, manufacturing, and quality.
CEO Anshul Thakral highlighted Sharbaugh's extensive background in CRO and pharmaceutical operations, emphasizing his understanding of stakeholders and global drug development. Sharbaugh expressed his commitment to leveraging his dual experience in CRO and pharmaceutical companies to create value for all stakeholders.
Fortrea (Nasdaq: FTRE), a global contract research organization, has announced the granting of inducement awards to a new employee. The award consists of 75,000 restricted stock units (RSUs) that will vest over three years in equal annual installments, beginning September 12, 2026.
The RSUs are granted under the Company's Amended and Restated 2025 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an employment inducement for the new hire.
Fortrea (Nasdaq: FTRE), a leading contract research organization (CRO), reported its Q2 2025 financial results with revenues of $710.3 million, up from $662.4 million in Q2 2024. The company posted a GAAP net loss of $(374.9) million, largely due to a $309.1 million non-cash goodwill impairment charge.
Key highlights include adjusted EBITDA of $54.9 million and adjusted earnings per share of $0.19. The company reported a book-to-bill ratio of 0.79x for Q2, with a trailing 12-month ratio of 1.10x. Fortrea raised its 2025 revenue guidance to $2,600-$2,700 million while affirming adjusted EBITDA guidance of $170-$200 million.
The company welcomed Anshul Thakral as CEO on August 4, 2025, succeeding Interim CEO Peter M. Neupert, who remains chairman of the Board.
Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has appointed Tracy Krumme as Senior Vice President of Investor Relations, replacing Hima Inguva. Reporting to CFO Jill McConnell, Krumme will lead the company's global investor relations strategy.
Krumme brings over 30 years of experience in investor relations and capital markets, with significant expertise in the CRO, life sciences, and healthcare sectors. Her previous roles include head of investor relations at PPD (acquired by Thermo Fisher Scientific), Galderma, and Nuance Communications (acquired by Microsoft). She has worked alongside Fortrea's current CEO Anshul Thakral during her tenure at PPD.
Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has announced employment inducement awards for its new President and CEO, Anshul Thakral, effective August 4, 2025.
The compensation package includes 1,250,000 performance share units (PSUs) that vest after three years subject to performance goals, and 1,250,000 restricted stock units (RSUs) that vest in three equal annual installments. Both awards are contingent on continuous employment or earlier vesting due to change of control and certain termination events.
The grants were approved by independent board members under the Company's 2025 Inducement Award Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025, before market opening. The company will host a conference call at 8:00 am ET the same day.
The earnings call will include a results review and Q&A session. Participants must register through Fortrea's Investor Relations website and are advised to join 10 minutes early. A replay will be available in the events and presentations section after the call.